NCT02562768View on ClinicalTrials.gov

A Study of LY3154207 in Healthy Participants and Participants With Parkinson's Disease

PHASE1CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

March 3, 2017

Study Completion Date

March 3, 2017

Conditions
Parkinson's Disease
Interventions
DRUG

LY3154207

Administered orally

DRUG

Placebo

Administered orally

Trial Locations (3)

32162

Compass Research, The Villages

32806

Compass Research, Orlanda

91206

Parexel International LLC, Glendale

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT02562768 - A Study of LY3154207 in Healthy Participants and Participants With Parkinson's Disease | Biotech Hunter | Biotech Hunter